Skip to main content

Safe Orthopaedics announces the signature of an agreement with the Clinicpartner buying group in Germany

Written by Customer Service on . Posted in Public Companies.

                                                                                                                                                                                                                                                                                                  

 

Safe Orthopaedics announces the signature of an agreement with the Clinicpartner buying group in Germany

 

  • Serving over 200 hospitals in Germany
  • Validation of the Ready-to-Use Model

 

     

 

 

Eragny-sur-Oise, France, March 10th, 2022 17h45 CET – Safe (FR0013467123 – ALSAF), a company specializing in the design, manufacturing and marketing of Ready-To-Use technologies for spinal surgeries, delivering the safest treatment for spinal fractures urgently treated, announces an exclusive agreement with the Clinicpartner buying group in Germany to supply their partner hospitals with it’s ready-to-use spinal implants and instruments solutions.

Serving over 200 hospitals across Germany, Clinicpartner hospitals are responsible for over 20,000 spinal procedures annually, in more than 30 spinal hospitals, accounting for over €18 million in implant sales. With the agreement now in place, Safe Orthopaedics has preferred-supplier status in these Clinicpartner hospitals.

After a detailed and exhaustive process of rationalization, the Clinicpartner team have significantly reduced their number of suppliers and concluded that Safe Orthopaedics’ SteriSpine portfolio is their preferred ready-to-use products range.

“Our team worked closely with the team at Clinicpartner for a 12-month evaluation and we are very proud that Clinicpartner have chosen to put their trust into our innovative products” says Nikolaus Beyer, Chief Commercial Officer of Safe Orthopaedics. “The Clinicpartner buying group has a proud history of delivering the very best solutions for their partners and patients with a close analysis of efficacy, value and customer support.  Our sales team in Germany is now conducting the delivery of consignments and medical staff trainings. Clinicpartner and Safe Orthopaedics teams are collaborating to maximize patient outcomes.”

At the end of 2021, Safe Orthopaedics distributed its technologies to 23 Spinal centers and delivered 123% sales growth in Germany.
All Safe Orthopaedics technologies are available in Germany and the new technologies Sycamore and Hickory, CE marked in 2021, are massively produced for larger distribution.

Pierre Dumouchel, CEO & Chairman of Safe Group adds “A few years ago, we decided to establish a direct sales force in Germany and recruit an experimented sales team. The agreement with Clinicpartner buying group is a breakthrough moment for our German team and a strategic milestone for Safe Orthopaedics. The Clinicpartner buying group is a large buying groups in the largest European spinal market over €300million.  By working closely with groups such as Clinicpartner we gain levels of market access, we continue to deliver double digit growth and offer to more and more patients the benefits of our ready-to-use technologies”

About Safe Group
Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopaedic surgery. The group employs approximately 150 people.

Safe Orthopaedics develops and manufactures kits combining sterile implants and single-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs.  Protected by 18 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics is headquartered in the Paris region (95610 Eragny-sur-Oise) and has subsidiaries in the United Kingdom, Germany, the United States and the Lyon region (Fleurieux-sur-l’Arbresle).

For more information: www.safeorthopaedics.com

Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France (Fleurieux-sur-l’Arbresle, 69210) and in Tunisia, offering numerous industrial services: design, industrialization, machining, finishing and sterile packaging. Supported by the French stimulus plan in 2020, the company invests in additive printing and will be operational in 2022 on this new technology.

For more information: www.safemedical.fr

Contacts 

Safe Group                                                                                                           

François-Henri Reynaud                 
Chief Financial and Administrative Officer                            
Tél. : +33 (0)1 34 21 50 00                                
investors@safeorthopaedics.com                            

Press Relations
Ulysse Communication
Pierre-Louis Germain / +33 (0)6 64 79 97 51 / plgermain@ulysse-communication.com  
Bruno Arabian / +33 (0)6 87 88 47 26 / barabian@ulysse-communication.com  

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.